Antidote Technologies, a digital patient engagement company, has announced a partnership with SEQSTER, a multidimensional healthcare data platform, to enhance patient identification for clinical trials and improve trial timelines. Antidote's platform offers patient recruitment, screening, and support services, and will now leverage SEQSTER's operating system to better match patients to clinical trials based on their genomic data, lifestyle factors, and medical history. This collaboration aims to enhance precision recruitment and reduce the time required to bring new treatments to market.
SEQSTER has been actively involved in similar partnerships to advance clinical trial processes. In December, SEQSTER partnered with Atropos Health to improve diversity and inclusion in clinical trials by creating turnkey patient registries for faster evidence generation. In March, SEQSTER teamed up with the Multiple Sclerosis Association of America to connect people with MS, researchers, and care centers using data integration. Additionally, in a partnership with decentralized clinical trial company Thread, SEQSTER worked to provide real-world data access for life science enterprises, researchers, and patients.
Other companies are also focusing on improving the clinical trial experience through digital health innovations. Flatiron Health, an oncology-focused digital health company acquired by Roche in 2018, recently collaborated with the Association of Cancer Care Centers to enhance access to clinical trials in community settings, improve study efficiency, and enhance data collection. Additionally, clinical trial startup Inato, the Digital Medicine Society (DiMe), clinical trial tech company Science 37, and tech-enabled clinical trial platform Paradigm are notable players in this space, all working towards streamlining clinical trial processes and improving outcomes.
Click here to read the original news story.